A Phase 2 interventional study of Avatrombopag and Placebo in Thrombocytopenia, sponsored by Eisai Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-22.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 10 in phase 2, and was the 2nd registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
This study had three phases: Prerandomization (Screening), Randomization (Core Study), and Open-Label Extension (OLE). The Randomization Phase included Treatment Periods A1 and A2 and a Follow-up Period (for those participants not continuing into the OLE phase). The OLE Phase included Treatment Periods B1, B2, and B3 (depending on when a participant entered the OLE), and a Follow-up Period. Participants may have been followed for sustained viral response, if appropriate. In the Core Study (randomization phase) participants were randomized (in a 1:1:1:1 ratio) to receive one of four treatments (placebo or avatrombopag [10mg, 20mg, and 30mg] for up to 21 days. Participants who successfully completed Treatment Period A1, (platelet count >=100x10\^9/L) initiated antiviral treatment with pegylated interferon (PEG-IFN) alpha-2a and progressed to Treatment Period A2. Participants with a platelet count >=150x10\^9/L initiated antiviral treatment and progressed into Treatment Period B2, study drug was interrupted then eventually restarted at 10 mg daily once their platelet counts returned to acceptable levels. Those who were not considered successful after 21 days in Treatment Phase A1 were withdrawn from the Core Study (Part A) and were eligible to enter the OLE at Treatment Period B1. Participants who chose to not enter the OLE entered into the Follow-up Phase. At the end of Treatment Period A2, eligible participants could enter the OLE at Treatment Period B3. In the OLE Phase, participants entering into Open-label Treatment Period B1 began once-daily treatment with avatrombopag at a dose of 20 mg without titration for up to 21 days. Once the participant's platelet counts were sufficient, they entered Treatment Period B2. Participant's eligible to enter into Treatment Period B2 received avatrombopag and antiviral treatment for 13 weeks. Participants who successfully completed Treatment Period A2 or B2 could continue on antiviral treatment for up to a maximum of 48 weeks (including the 13 weeks in Treatment Periods A2 or B2) and open-label avatrombopag, at the investigator's discretion. In Treatment Period B3, the dose of avatrombopag was allowed to be titrated up or down in accordance with the participant's platelet count response, within the range of a minimum of 5 mg and a maximum of 50 mg. In the Follow-up Period, participants were seen at either a single 30-day follow-up visit or followed for the full 30 days after the last dose of avatrombopag.
Inclusion Criteria:
Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo, will be administered orally, once daily for up to 21 days.
Drug: Placebo
Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
Drug: Avatrombopag
Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
Drug: Avatrombopag · Drug: Pegylated interferon (PEG-IFN) · Drug: Telaprevir · Drug: Ribavirin
Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
Drug: Avatrombopag
Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
Drug: Avatrombopag · Drug: Pegylated interferon (PEG-IFN) · Drug: Telaprevir · Drug: Ribavirin
Also known as: E5501, Avatrombopag maleate
Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Also known as: Incivek, Incivo
Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Also known as: Virazole, Rebetol, Copegus, Ribasphere, Moderiba dose pack, Moderiba
Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study
A responder was defined as a participant having a platelet count of greater than or equal to 100x10\^9/L by Day 21 starting from an average baseline platelet count of greater than 20 x 10\^9/L to less than or equal to 70 x 10\^9/L.
Time frame: Baseline to Day 21
Change From Baseline of Local Platelet Count by Visit During Treatment Period A1 of Core Study
Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.
Time frame: Day 7 and Day 14
Number of Participants Who Achieved Platelet Count Greater Than 30 X 10^9/L From Baseline to Day 21 During Treatment Period A1 of Core Study
Blood draws were taken to monitor platelet counts.
Time frame: Baseline to Day 21
Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study
Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to 100 X 10\^9/L was attained, antiviral treatment was initiated.
Time frame: Baseline to Day 21
| Milestone | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Avatrombopag (Open Label Extension) |
|---|---|---|---|---|---|
| Started | 17 | 16 | 18 | 14 | 0 |
| Completed | 16 | 16 | 18 | 12 | 0 |
| Not completed | 1 | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event, non-fatal | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Inadequate therapeutic effect | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
| Milestone | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Avatrombopag (Open Label Extension) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 62 |
| Completed | 0 | 0 | 0 | 0 | 28 |
| Not completed | 0 | 0 | 0 | 0 | 34 |
| Withdrew: Adverse event, non-fatal | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Inadequate therapeutic effect | 0 | 0 | 0 | 0 | 29 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 3 |
Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.
| cells x 10^9/L | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) |
|---|---|---|---|---|
| Day 7 | -0.1 ± 7.15 | 19.8 ± 17.59 | 26.5 ± 22.06 | 30.9 ± 37.65 |
| Day 14 | -0.2 ± 13.79 | 29.2 ± 18.32 | 57.2 ± 31.39 | 55.4 ± 37.47 |
Blood draws were taken to monitor platelet counts.
| Participants | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) |
|---|---|---|---|---|
| Yes | 1 | 9 | 16 | 11 |
| No | 16 | 7 | 2 | 3 |
A responder was defined as a participant having a platelet count of greater than or equal to 100x10\^9/L by Day 21 starting from an average baseline platelet count of greater than 20 x 10\^9/L to less than or equal to 70 x 10\^9/L.
| Participants | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) |
|---|---|---|---|---|
| Yes | 1 | 6 | 12 | 9 |
| No | 16 | 10 | 6 | 5 |
Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to 100 X 10\^9/L was attained, antiviral treatment was initiated.
| Participants | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) |
|---|---|---|---|---|
| Yes | 1 | 6 | 13 | 9 |
| No | 16 | 10 | 5 | 5 |
Collected over For each participant, treatment emergent adverse events were collected from the first day of administration of study drug up to 30 days after the last dose of study drug or up to approximately 2.5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Core Study) | — | 0/17 (0%) | 6/17 (35.3%) |
| Avatrombopag 10 mg (Core Study) | — | 1/16 (6.3%) | 11/16 (68.8%) |
| Avatrombopag 20 mg (Core Study) | — | 0/18 (0%) | 12/18 (66.7%) |
| Avatrombopag 30 mg (Core Study) | — | 1/14 (7.1%) | 11/14 (78.6%) |
| Avatrombopag (Open Label Extension) | — | 13/64 (20.3%) | 55/64 (85.9%) |
| Event | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Avatrombopag (Open Label Extension) |
|---|---|---|---|---|---|
| ParaesthesiaNervous system disorders | 0/17 | 0/16 | 0/18 | 1/14 | 1/64 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/17 | 1/16 | 0/18 | 0/14 | 2/64 |
| AnaemiaBlood and lymphatic system disorders | 0/17 | 0/16 | 0/18 | 0/14 | 2/64 |
| NeutropeniaBlood and lymphatic system disorders | 0/17 | 0/16 | 0/18 | 0/14 | 2/64 |
| LeukopeniaBlood and lymphatic system disorders | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| PancytopeniaBlood and lymphatic system disorders | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| Abdominal painGastrointestinal disorders | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| Hepatic massHepatobiliary disorders | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| GastroenteritisInfections and infestations | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| Urinary tract infectionInfections and infestations | 0/17 | 0/16 | 0/18 | 0/14 | 1/64 |
| Event | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Avatrombopag (Open Label Extension) |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/17 | 2/16 | 2/18 | 1/14 | 21/64 |
| NeutropeniaBlood and lymphatic system disorders | 0/17 | 2/16 | 4/18 | 2/14 | 20/64 |
| NauseaGastrointestinal disorders | 0/17 | 3/16 | 4/18 | 2/14 | 20/64 |
| FatigueGeneral disorders | 0/17 | 1/16 | 3/18 | 2/14 | 16/64 |
| PruritusSkin and subcutaneous tissue disorders | 0/17 | 4/16 | 0/18 | 2/14 | 15/64 |
| Influenza like illnessGeneral disorders | 2/17 | 1/16 | 4/18 | 3/14 | 11/64 |
| LeukopeniaBlood and lymphatic system disorders | 0/17 | 1/16 | 3/18 | 1/14 | 14/64 |
| InsomniaPsychiatric disorders | 1/17 | 1/16 | 0/18 | 3/14 | 13/64 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 0/16 | 2/18 | 3/14 | 9/64 |
| ChillsGeneral disorders | 1/17 | 3/16 | 3/18 | 1/14 | 13/64 |
| Age, Continuous(Years) | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Total |
|---|---|---|---|---|---|
| Mean | 50.2 ± 7.96 | 55.3 ± 8.06 | 54.9 ± 7.38 | 53.6 ± 7.26 | 53.5 ± 7.78 |
| Sex: Female, Male(Participants) | Placebo (Core Study) | Avatrombopag 10 mg (Core Study) | Avatrombopag 20 mg (Core Study) | Avatrombopag 30 mg (Core Study) | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 5 | 5 | 17 |
| Male | 14 | 12 | 13 | 9 | 48 |
The record gives a start of Nov 2011, a primary completion of Feb 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 4 years after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag